1BT Stock Chart & Stats
€3.76
-€0.18(-4.57%)
At close: 4:00 PM EDT
€3.76
-€0.18(-4.57%)
Day’s Range― - ―
52-Week Range€3.64 - €25.65
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€62.95M
Enterprise Value€28.67
Total Cash (Recent Filing)€5.87M
Total Debt (Recent Filing)€641.00K
Price to Earnings (P/E)<0.1
Beta0.71
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)405.30
Shares Outstanding16,832,014
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
RMAT Designation For AllocetraRMAT status creates a durable regulatory advantage: it provides expedited pathways, increased FDA engagement (Type B meeting requested) and could shorten development timelines. This materially improves the program's regulatory clarity and long-term probability of a faster approval pathway in a large OA market.
Large RAIN Token TreasuryA >$1B digital-asset treasury is a structural capital cushion for a cash-burning clinical-stage biotech. It provides alternative funding optionality, reduces reliance on immediate equity raises, and can underwrite trials or partnerships over the medium term, materially affecting financing flexibility and strategic choices.
Very Low LeverageMinimal debt reduces financial distress risk and preserves optionality for a biotech in clinical development. Low leverage supports the firm’s ability to pursue additional financing, collaborations or milestone deals without pressing near-term debt-service constraints, improving long-term operational resilience.
Bears Say
No Recurring Revenue & Operating LossesLack of commercial revenue and persistent operating losses mean Enlivex remains fully pre-revenue and dependent on future trial success. This structural reality raises execution risk: clinical setbacks or longer timelines will directly pressure funding needs and limit ability to self-sustain operations over the medium term.
Persistent Negative Operating Cash FlowContinued negative operating and free cash flow indicate ongoing cash burn; management must access external financing until operations produce positive cash generation. This dependence increases dilution risk, constrains strategic flexibility, and makes long-term planning vulnerable to capital-market conditions.
Balance-sheet Volatility & Non-operating EarningsLarge swings in equity and a pronounced net-income spike driven by non-operating items reduce earnings quality and signal balance-sheet volatility tied to mark-to-market crypto exposure or one-time events. This undermines predictability of capital strength and complicates partner, lender and investor assessments.
Enlivex News
1BT FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was €3.64 and its highest was €25.65 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is €62.95M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is Apr 23, 2027 which is in 268 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 22, 2026. The company reported -€0.018 earnings per share for the quarter, the consensus estimate of -€0.018 by €0.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Overvalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 16,832,014 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -€0.018 in its last earnings report, expectations of -€0.018. Following the earnings report the stock price went up 2.521%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in DE:1BT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enlivex Stock Smart Score
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
1BT Earnings Call
Q4 2026
0:00 / 0:00
Technical Analysis
―
Daré Bioscience
―
Sonnet BioTherapeutics Holdings
―
Akari Therapeutics
―
Passage Bio
―